Loading…
Expert Aesthetics sold unapproved and misbranded compounded drug products (semaglutide and tirzepatide) over the internet by making false or misleading claims that implied their products were equivalent to FDA-approved drugs like Ozempic and Mounjaro. The company violated sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by advertising compounded drugs with claims suggesting they were the same as approved products, when compounded drugs are by definition not FDA-approved. The FDA identified these marketing claims on the company's website (erasingage.com) during an August 2025 inspection and determined the misbranded products were unlawfully introduced into interstate commerce.